Epidemiology of cutaneous melanoma in Germany and Worldwide. Skin Pharmacol Physiol 2001: 14: 280–290.
et al. Melanoma incidence and mortality in Scotland 1979–2003. Br J Cancer 2007: 96: 1772–1777.
et al. Randomised phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic melanoma. J Clin Oncol 2000: 18: 158–166.
et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006: 24: 4738–4745.
et al. Phase III multicentre randomised trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999: 17: 2745–2751.
et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000: 82: 1158–1162.
et al. High dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999: 17: 2105–2116.
et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002: 20: 125–133.
et al. Multicentre phase III randomised trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha-2b in metastatic melanoma patients. Ann Oncol, 2006: 17: 571–577.
et al. Dacarbazine, cisplatin and interferon--alpha-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005: 23: 6747–6755.
et al. A prospective randomised phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD) IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial. J Clin Oncol 2003: 22 (abstract 2847)., ,
Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003: 4: 748–759.
, , , .
Meta-analysis of chemotherapy and biochemotherapy in metastatic malignant melanoma. J Clin Oncol 2007: 25: 3426–3434.
, , , .
et al. Final report of the French multicentre phase II study of the nitrosurea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990: 66: 1873–1878.
et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma. J Clin Oncol 2004: 22: 1118–1125.
Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 1994: 69: 452–456.
, , , .
et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004: 22: 610–616.
et al. Radiotherapy plus concomitant and adjuvant temozolomide and for glioblastoma. N Engl J Med 2005: 352: 987–996.
et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004: 22: 2101–2107.
et al. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer 2000: 88: 469–473.
et al. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically respectable tumours. Clin Cancer Res 2002: 8: 2519–2523.
et al. Randomised trial of combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol 2007: 25: 2540–2454.
et al. First and final report of a phase II study of the PARP inhibitor AGO14699 in combination with temozolomide in patients with metastatic melanoma. J Clin Oncol 2006: 24: 8013. , ,
et al. Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 1998: 4: 1865–1871.
The role of the Bcl-2 family members in the progression of cutaneous melanoma. Clin Exp Metastasis 2003: 20: 531–539.
et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 2003: 9: 2826–2836.
et al. A phase II study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion in patients with unresectable stage III or IV melanoma. J Clin Oncol 2007: 25: 8538. , ,
Molecular targets in melanoma from angiogenesis to apoptosis. Clin Cancer Res 2006: 12 (Suppl. 7): 2376–2383s.
Targeting of mitogen-activated protein kinase pathways in the treatment of malignant melanoma. Clin Cancer Res 2006: 12 (Suppl. 7): 2371–2375.
, , .
et al. Mutations of the BRAF gene in human cancer. Nature 2002: 417: 949–954.
Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004: 6: 313–319.
et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004: 116: 855–867.
et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005: 65: 2412–2421.
et al. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal of transduction pathway. Semin Oncol 2006: 33: 392–406.
et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 2006: 95: 581–586.
et al. Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. J Clin Oncol 2007: 25: 8527. , ,
et al. Randomised Phase III trial of paclitaxel + carboplatin with or without sorafenib in patients with advanced melanoma. J Clin Oncol 2007: 25: 8510. , ,
et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol 2004: 22: 2092–2100.
et al. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther 2003: 2: 753–763.
et al. Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. J Clin Oncol 2005: 23: 7508. , ,
et al. An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma. J Clin Oncol 2007: 25: 8529. , ,
et al. Randomised phase II study of dacarbazine with or without sorafenib in patients with advanced melanoma. J Clin Oncol 2007: 25: 8511. , ,
et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007: 356: 2271–2281.
et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 2005: 104: 1045–1048.
et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006: 24: 4340–35.
et al. A multi-centre phase II trial of high dose imatinib in metastatic melanoma: significant toxicity with no clinical activity. Cancer 2006: 106: 2005–2011.
et al. Phase II study of erlotinib given daily for patients with melanoma. J Clin Oncol 2007: 25: 18002. , ,
The ubiquitin system for protein degradation and some of its roles in the control of cell division. Cell Death Differ 2005: 12: 1191–1197.
et al. NF-kB in the vascular progression of melanoma. J Clin Oncol 2004: 22: 617–623.
The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005: 23: 4776–4789.
The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004: 4: 349–360.
et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 2005: 103: 2584–2589.
et al. Phase II trial of tanespimycin (KOS-953), a Hsp90 inhibitor in patients with metastatic malignant melanoma. J Clin Oncol 2007: 25: 8558. , ,
et al. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol 2007: 212: 330–344.
DNA methylation and cancer. J Clin Oncol 2004: 22: 4632–4642.
Cancer epigenetics. Hum Mol Genet 2005: 14: R65–R76.
Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest 1996: 98: 426–433.
, , , , .
The INK4a/ARF locus and melanoma. Oncogene 2003: 22: 3092–3098.
et al. A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma. J Clin Oncol 2006: 24: 8044. , ,
et al. Phase I trial of sequential low-dose 5-aza-2′-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 2006: 12: 4619–4627.
et al. Subgroup analysis of efficacy and safety analysis of a randomised, double blinded controlled phase II study of STA-4783 in combination with paclitaxel in patients with metastatic melanoma. J Clin Oncol 2007: 25: 8528. , ,
et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000: 14: 17–20.
et al. A randomised study of temozolomide (TMZ) alone, with interferon (TMZ-IFN) or with thalidomide (TMZ-THAL) in metastatic malignant melanoma (MMM). J Clin Oncol 2003: 21: 2551–2557.
et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003: 21: 3351–3356.
et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of the thalidomide analogue CC-5013 in patients with metastatic melanoma and other advanced cancers. Br J Cancer 2004: 90: 955–961.
et al. Preliminary results from a phase II study of the combination of lenalidomide and DTIC in patients with metastatic malignant melanoma previously untreated with systemic chemotherapy. J Clin Oncol 2007: 25: 8533. , ,
et al. Prognostic relevance of pretreatment soluble vascular endothelial growth factors (A, C, D) and their receptors (R1, R2, and R3) in advanced melanoma. J Clin Oncol 2007: 25: 8540. , ,
et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal carcinoma. N Engl J Med 2004: 350: 2335–2342.
et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006: 355: 2542–2550.
et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 2007: 14: 2367–2376.
et al. A multicentre phase II trial of erlotinib and bevacizumab in patients with malignant melanoma. J Clin Oncol 2007: 25: 8539. , ,
et al. Phase II trial of carboplatin, weekly paclitaxel and biweekly bevacizumab in patients with unresectable stage IV melanoma. J Clin Oncol 2007: 25: 8560. , ,
et al. Phase I trial of a monoclonal antibody specific for αVβ3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effects on tissue perfusion. Clin Cancer Res 2005: 11: 7851–7860.
et al. A randomised phase II study of EMD 121974 in patients with metastatic melanoma. J Clin Oncol 2007: 25: 8548. , ,
et al. Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumours. Clin Cancer Res 2007: 13: 2128–2135.
et al. Phase I/II study of CNTO95, a fully human monoclonal antibody to alpha-c integrin in patients with metastatic melanoma. Eur J Cancer (Suppl) 2006: 4: 218.
et al. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res 2004: 10: 4048–4054.
et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003: 21: 3343–3350.
et al. Evaluation of a novel heterologous prime boost immunotherapy in stage III/IV metastatic melanoma patients. J Clin Oncol 2005: 23 (abstract 2570).
et al. Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity. Nat Immunol 2004: 11: 1143–1148.
et al. Autologous tumor-derived HSPPC-96 vs. physician’s choice (PC) in a randomized phase III trial in stage IV melanoma. J Clin Oncol 2006: 23: 8002. , ,
et al. An international, randomised, phase III trial of BCG plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional nodes or distant sites. J Clin Oncol 2007: 25: 8508. , ,
Randomised adjuvant trials in melanoma: surgical and systemic. Semin Oncol 2007: 34: 509–515.
Dendritic cells as initiators of tumour immune responses: a possible strategy for tumour immunotherapy? Immunol Today 1995: 16: 117–121.
, , , .
et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC Study Group of the DeCOG. Ann Oncol 2006: 17: 563–570.
et al. Autoimmunity correlates with tumour regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005: 23: 6043–6053.
et al. Prognostic factors related to clinical response in patients with metastatic malignant melanoma treated by CTL-Associated Antigen-4 blockade. Clin Cancer Research 2007: 13: 6681–6688.
et al. Antitumour activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005: 23: 8968–8977.
et al. Phase I clinical trial of ticilimumab: tumour responses are sufficient but not necessary for prolonged survival. J Clin Oncol 2006: 24: 8036. , ,
Analysis of the cellular mechanism of antitumour response and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005: 175: 7746–7754.
, , .
et al. Programmed death-1 ligand interacts specifically with the B7-1 costimulatory molecules to inhibit T cell responses. Immunity 2007: 27: 111–122.
et al. Tumour associated B7-1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002: 8: 793–800.
et al. Foxp3 expressing CD4+ CD25(high) regulatory T cells are overrepresented in human metastatic melanoma nodes and inhibit the function of infiltrating T cells. J Immunol 2004: 173: 1444–1453.
et al. Effect of CD4+CD25+ and CD4+CD25− T-regulator cells on the generation of cytolytic T-cell response to a self but human tumour-associated epitope in vitro. J Immunol 2006: 176: 984–990.
et al. Characterisation of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006: 24: 1169–1177.
Il-2 administration increases CD4+CD25hiFoxp3+ regulatory T cells in cancer patients. Blood 2006: 107: 2409–2414.
et al. New immunosuppressive therapies in renal transplantation: monoclonal antibodies. J Nephrology 2005: 18: 529–536.
et al. The IL-2 immunotoxin denileukin diftitoxin (Ontak) reduces regulatory T cells and enhances vaccine mediated T-cell immunity. Blood 2007: 110: 3192–3201.
, , ,
et al. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Cancer 2007: 138: 502–505.
et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell nonHodgkins lymphoma. Br J Cancer 2007: 136: 439–447.
et al. Inability of fusion protein of IL-2 and dipteria toxin (Denileukin Diftitix, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005: 28: 582–592.
et al. Enhancement of vaccine-mediated antitumour immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005: 115: 3623–3633.
et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony stimulating factor based antitumour vaccine. J Clin Oncol 2007: 25: 2546–2553.
et al. EORTC 18991: long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma’ final results of a randomised phase III trial. J Clin Oncol 2007: 25: 8504. , ,
et al. Randomised dose escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol 2006: 24: 1188–1194.
et al. IL-21 counteracts the regulatory T cell-mediated suppression of Human CD4+ T Lymphocytes. J Immunol 2007: 178: 732–739.
et al. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res 2007: 13: 3630–3636.
et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 2000: 6: 1678–1692.
et al. Phase I evaluation of intravenous recombinant human interleukin-12 in patients with advanced malignancies. Clin Cancer Res 1997: 3: 409–417.
et al. Two phase I studies of low dose recombinant IL-12 with Melan-A and influenza peptides in subjects with advanced melanoma. Cancer Immunol 2003: 3: 7.
et al. Immunisation with Melan-A peptide pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 2003: 21: 2342–2348.
et al. Alum with Interleukin-12 augments immunity to a melanoma peptide vaccine; correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res 2007: 13: 215–222.
Thymalfasin: an immune system enhancer for the treatment of liver disease. J Gastroenterol Hepatol 2004: 19: S69–S72.
et al. The safety and efficacy of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomised clinical trial. J Viral Hepat 2005: 12: 300–306.
et al. A first-line, randomised, dose finding, phase II study on thymosin alpha-1 plus DTIC without or without IFN-alpha compared to DTIC + IFN in patients with stage IV melanoma. J Clin Oncol 2007: 25: 8385. , ,
et al. CpG motifs are efficient adjuvants for DNA cancer vaccines. J Invest Dermatol 2004: 123: 371–379.
et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006: 24: 5716–5724.
Pharmacokinetics of 852A, an imidazoquinoline toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J Clin Pharmacol 2007: 47: 962–969.
, , , .
et al. Inhibiting Stat3 signalling in the haemopoietic system elicits muticomponent antitumour activity. Nat Med 2005: 11: 1314–1321.
et al. Phase I study of adoptive T-cell therapy using antigen-specific CD8− T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 2006: 24: 5060–5069.
et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005: 23: 2346–2357.